BioCentury | Jan 17, 2018
Company News

Management tracks: NanoString, Orchard

...the Allergopharma GmbH & Co. KG unit at Merck KGaA (Xetra:MRK). Antibody-drug conjugate (ADC) developer Glythera...
BioCentury | Jul 25, 2016
Company News

Avacta, Glythera deal

...Avacta and Glythera partnered to develop targeted therapeutics using Avacta’s Affimer technology and Glythera’s PermaLink conjugation...
...financial terms, and Glythera did not respond to inquiries. Avacta Group plc (LSE:AVCT), Heslington, U.K. Glythera...
BioCentury | Nov 3, 2014
Clinical News

Glythera preclinical data

...In a mouse xenograft model of cancer, an antibody-drug conjugate (ADC) containing Glythera's PermaLink linker led...
...a maleimide-based linker. Data were presented at the World ADC Summit meeting in San Diego. Glythera's...
...comprises cysteine-specific, highly stable linker designs for conjugation of various cargos to proteins and peptides. Glythera...
BioCentury | Jun 25, 2012
Company News

Glythera management update

Glythera Ltd. , Newcastle upon Tyne, U.K. Business: Chemistry Hired: David Simpson as COO in March, a new position, formerly a program director at Eden Biodesign Group Ltd., which was acquired by Watson Pharmaceuticals Inc. WIR...
BioCentury | Jun 25, 2012
Financial News

Glythera completes venture financing

Glythera Ltd. , Newcastle upon Tyne, U.K. Business: Chemistry Date completed: 6/21/12 Type: Venture financing Raised: £2 million ($3.1 million) Investor: IP Group WIR Staff...
BioCentury | Oct 11, 2010
Financial News

Glythera financial update

...Crescent Seedcorn Fund participated. Glythera raised an undisclosed amount in a first tranche in 2008. Glythera...
BioCentury | Sep 13, 2010
Company News

Glythera deal

...antigens to carrier proteins for vaccines being developed by FDA. Further details were not disclosed. Glythera...
Items per page:
1 - 7 of 7
BioCentury | Jan 17, 2018
Company News

Management tracks: NanoString, Orchard

...the Allergopharma GmbH & Co. KG unit at Merck KGaA (Xetra:MRK). Antibody-drug conjugate (ADC) developer Glythera...
BioCentury | Jul 25, 2016
Company News

Avacta, Glythera deal

...Avacta and Glythera partnered to develop targeted therapeutics using Avacta’s Affimer technology and Glythera’s PermaLink conjugation...
...financial terms, and Glythera did not respond to inquiries. Avacta Group plc (LSE:AVCT), Heslington, U.K. Glythera...
BioCentury | Nov 3, 2014
Clinical News

Glythera preclinical data

...In a mouse xenograft model of cancer, an antibody-drug conjugate (ADC) containing Glythera's PermaLink linker led...
...a maleimide-based linker. Data were presented at the World ADC Summit meeting in San Diego. Glythera's...
...comprises cysteine-specific, highly stable linker designs for conjugation of various cargos to proteins and peptides. Glythera...
BioCentury | Jun 25, 2012
Company News

Glythera management update

Glythera Ltd. , Newcastle upon Tyne, U.K. Business: Chemistry Hired: David Simpson as COO in March, a new position, formerly a program director at Eden Biodesign Group Ltd., which was acquired by Watson Pharmaceuticals Inc. WIR...
BioCentury | Jun 25, 2012
Financial News

Glythera completes venture financing

Glythera Ltd. , Newcastle upon Tyne, U.K. Business: Chemistry Date completed: 6/21/12 Type: Venture financing Raised: £2 million ($3.1 million) Investor: IP Group WIR Staff...
BioCentury | Oct 11, 2010
Financial News

Glythera financial update

...Crescent Seedcorn Fund participated. Glythera raised an undisclosed amount in a first tranche in 2008. Glythera...
BioCentury | Sep 13, 2010
Company News

Glythera deal

...antigens to carrier proteins for vaccines being developed by FDA. Further details were not disclosed. Glythera...
Items per page:
1 - 7 of 7